Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Newmont Corporation (NEM) vs Zoetis Inc (ZTS) Price & Performance

Newmont CorporationTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Newmont Corporation vs Zoetis Inc — how do they compare? Newmont Corporation trades at $117.84 (market cap $121.75B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Newmont Corporation is far larger — about 4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Zoetis Inc for 70 Days on average.

NEMZTS
Market Cap
$121.75B$30.20B
Volume
5,421,1256,175,327
Sector
Basic MaterialsHealth
52-Week High
$135.14$147.53
52-Week Low
$78.63$69.09
Typical Hold Time
58 Days70 Days
Enterprise Value
$118.34B$37.76B
Dividend Yield
0.9%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Newmont Corporation

Newmont Corporation (NEM) trades at $117.84, up 3.79% over the past 24 hours, with a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has consistently beaten earnings estimates in recent quarters. Revenue grew to $22.67 billion in 2025, with net income reaching $7.09 billion, reflecting a robust profit margin of 31.25%.

The outlook remains positive due to strong cash flow generation and operational improvements, though near-term technical weakness and gold price volatility present risks. Analyst consensus is strongly bullish with a $136.83 price target, indicating potential upside. Key risks include dependence on gold prices and execution of growth projects.

Zoetis Inc

Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.

Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NEM
2% Buy98% Sell
Avg holding period · 58 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Newmont Corporation

Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.

Read more on NEM →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →